1449846-47-2

Upstream product

• 1449846-38-1 (R)-2-(N-(2-azidoethyl)-4-(2-fluoroethoxy)phenylsulfonamido)-3-methylbutanoic acid 
• 1449846-35-8 (R)-tert-butyl 2-(N-(2-azidoethyl)-4-(2-fluoroethoxy)phenylsulfonamido)-3-methylbutanoate 

Downstream Products

• 1449846-56-3 (R)-2-(4-(2-fluoroethoxy)-N-(2-(4-(3-fluoropropyl)-1H-1,2,3-triazol-1-yl)ethyl)phenylsulfonamido)-N-hydroxy-3-methylbutanamide 
• 1449846-57-4 (R)-2-(N-(2-(4-(16-fluoro-2,5,8,11,14-pentaoxahexadecyl)-1H-1,2,3-triazol-1-yl)ethyl)-4-(2-fluoroethoxy)phenylsulfonamido)-N-hydroxy-3-methylbutanamide 
• 1449846-58-5 (R)-2-(4-(2-fluoroethoxy)-N-(2-(4-(4-((2-fluoropyridin-3-yl)oxy)butyl)-1H-1,2,3-triazol-1-yl)ethyl)phenylsulfonamido)-N-hydroxy-3-methylbutanamide 
• 1449846-59-6 (R)-2-(4-(2-fluoroethoxy)-N-(2-(4-((4-fluorophenylsulfonamido)methyl)-1H-1,2,3-triazol-1-yl)ethyl)phenylsulfonamido)-N-hydroxy-3-methylbutanamide 
• 1449846-60-9 (R)-2-(N-(2-(4-((4-fluoro-N-methylphenylsulfonamido)methyl)-1H-1,2,3-triazol-1-yl)ethyl)-4-(2-fluoroethoxy)phenylsulfonamido)-N-hydroxy-3-methylbutanamide 

Relevant academic research and scientific papers

Inverse 1,2,3-triazole-1-yl-ethyl substituted hydroxamates as highly potent matrix metalloproteinase inhibitors: (Radio)synthesis, in vitro and first in vivo evaluation

Noninvasive imaging and quantification of matrix metalloproteinase (MMP) activity in vivo are of great (pre)clinical interest. This can potentially be realized by using radiolabeled MMP inhibitors (MMPIs) as positron emission tomography (PET) imaging agen